We have been featured in Singapore’s Chinese newspaper, Lianhe Zaobao, on 22 November 2018.
English translation is available here. It is translated from the original article at https://www.sgsme.sg/cn/sme-interview/story20181122-14522, [“修读课程突破思维 业者自我创新“药”走向国际, Lianhe Zaobao, 22 November 2018”. Any errors are the translator’s own.]
Hyphens Pharma and Agency for Science, Technology and Research (A*STAR) inked a memorandum of understanding (MoU) on becoming strategic dialogue partners to explore collaboration in market-relevant projects in dermatology research and skin disorders.
Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES). By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.
Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.